Published in Am J Pathol on January 17, 2008
Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol (2009) 1.33
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab (2009) 1.07
Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod (2009) 1.06
Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One (2011) 1.04
Preeclampsia: 2-methoxyestradiol induces cytotrophoblast invasion and vascular development specifically under hypoxic conditions. Am J Pathol (2010) 1.03
Fetal ERAP2 variation is associated with preeclampsia in African Americans in a case-control study. BMC Med Genet (2011) 1.01
Endometriosis, a disease of the macrophage. Front Immunol (2013) 0.97
Angiogenesis and endometriosis. Obstet Gynecol Int (2013) 0.93
Proangiogenic Tie2(+) macrophages infiltrate human and murine endometriotic lesions and dictate their growth in a mouse model of the disease. Am J Pathol (2011) 0.93
High-resolution ultrasound imaging: a novel technique for the noninvasive in vivo analysis of endometriotic lesion and cyst formation in small animal models. Am J Pathol (2009) 0.93
Circulating endothelial progenitor cells are up-regulated in a mouse model of endometriosis. Am J Pathol (2011) 0.93
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs (2010) 0.91
Plasma miR-17-5p, miR-20a and miR-22 are down-regulated in women with endometriosis. Hum Reprod (2012) 0.90
Metabolic pathways involved in 2-methoxyestradiol synthesis and their role in preeclampsia. Reprod Sci (2013) 0.81
Proangiogenetic molecules, hypoxia-inducible factor-1alpha and nitric oxide synthase isoforms in ovarian endometriotic cysts. Virchows Arch (2010) 0.81
Transforming growth factor-β induced Warburg-like metabolic reprogramming may underpin the development of peritoneal endometriosis. J Clin Endocrinol Metab (2014) 0.80
Lipoxin A₄ prevents the progression of de novo and established endometriosis in a mouse model by attenuating prostaglandin E₂ production and estrogen signaling. PLoS One (2014) 0.78
MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway. Int J Clin Exp Pathol (2015) 0.77
Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF‑2α expression in lung cancer cells under normoxia and hypoxia. Oncol Rep (2015) 0.76
Transforming Growth Factor-beta 1 Involved in the Pathogenesis of Endometriosis through Regulating Expression of Vascular Endothelial Growth Factor under Hypoxia. Chin Med J (Engl) (2017) 0.75
Efficacy of Intravitreal injection of 2-Methoxyestradiol in regression of neovascularization of a retinopathy of prematurity rat model. BMC Ophthalmol (2017) 0.75
The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX Expression. Anticancer Res (2015) 0.75
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science (2001) 23.83
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Angiogenesis in life, disease and medicine. Nature (2005) 15.36
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J Physiol (1952) 13.84
Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (1998) 11.61
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J (1998) 10.08
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Purification and characterization of hypoxia-inducible factor 1. J Biol Chem (1995) 8.53
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun (1989) 7.39
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A (1993) 6.77
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res (1995) 4.55
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem (1997) 3.23
Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J (2000) 2.44
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells. Fertil Steril (2005) 2.09
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res (1997) 1.97
Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol (2003) 1.95
Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol (1998) 1.85
A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer (1981) 1.85
Studies on the surgical induction of endometriosis in the rat. Fertil Steril (1985) 1.69
Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J (2006) 1.52
2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Clin Cancer Res (2004) 1.50
Vascular endothelial growth factor (VEGF) in endometriosis. Hum Reprod (1998) 1.48
Angiogenic factors in endometriosis. Ann N Y Acad Sci (2002) 1.44
2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A (1994) 1.43
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. Arch Biochem Biophys (1996) 1.35
Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab (2003) 1.34
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32
Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab (2004) 1.28
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res (2000) 1.12
Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod (1996) 1.12
Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril (2005) 1.08
Induction of endometriosis in mice: a new model sensitive to estrogen. Reprod Toxicol (1995) 1.07
A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol (2006) 1.03
Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res (2007) 1.02
Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril (2006) 1.01
Peritoneal endometriosis: validation of an in-vivo model. Hum Reprod (2001) 1.01
Experimental endometriosis: the nude mouse as a xenographic host. Ann N Y Acad Sci (2002) 1.00
Deficient cellular immunity in endometriosis. Am J Obstet Gynecol (1981) 1.00
Peritoneal endometriosis and "endometriotic" nodules of the rectovaginal septum are two different entities. Fertil Steril (1996) 0.95
Current thinking on the pathogenesis of endometriosis. Gynecol Obstet Invest (2002) 0.95
Time course of pelvic endometriotic lesion revascularization in a nude mouse model. Fertil Steril (2005) 0.93
Resolution of clonal origins for endometriotic lesions using laser capture microdissection and the human androgen receptor (HUMARA) assay. Fertil Steril (2003) 0.92
Time series analysis of transmesothelial invasion by endometrial stromal and epithelial cells using three-dimensional confocal microscopy. Fertil Steril (2003) 0.89
Anti-angiogenic treatment of endometriosis: biochemical aspects. Gynecol Obstet Invest (2004) 0.86
Endometriosis and infertility. Fertil Steril (2004) 0.86
Expression of integrins and E-cadherin in cells from menstrual effluent, endometrium, peritoneal fluid, peritoneum, and endometriosis. Fertil Steril (1994) 0.84
Development of endometriosis-like lesions after transplantation of human endometrial fragments onto the chick embryo chorioallantoic membrane. Hum Reprod (2001) 0.84
Does endometriosis really have premalignant potential? A clonal analysis of laser-microdissected tissue. FASEB J (2003) 0.81
Etiology of endometriosis: hypotheses and facts. Gynecol Obstet Invest (2004) 0.81
P-cadherin expression in human endometrium and endometriosis. Gynecol Obstet Invest (1994) 0.79
Expression of aromatase (P450 aromatase/CYP19) in peritoneal and ovarian endometriotic tissues and deep endometriotic (adenomyotic) nodules of the rectovaginal septum. Fertil Steril (2006) 0.79
Expression of intercellular adhesion molecule-1 (ICAM-1) on cultured human endometrial stromal cells and its role in the interaction with natural killers. Am J Reprod Immunol (1994) 0.77
Now you see them, now you don't. Fertil Steril (2005) 0.76
Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58
A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst (2006) 4.44
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest (2005) 3.77
Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst (2002) 3.77
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell (2005) 3.74
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med (2005) 3.43
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Unstable kinetochore-microtubule capture and chromosomal instability following deletion of CENP-E. Dev Cell (2002) 3.23
Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle (2006) 3.10
Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A (2003) 3.10
Developmentally regulated activation of a SINE B2 repeat as a domain boundary in organogenesis. Science (2007) 2.70
Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature (2004) 2.48
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol (2005) 2.14
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol (2002) 2.10
Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature (2008) 2.09
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A (2006) 2.09
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res (2009) 2.04
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
Endostatin's antiangiogenic signaling network. Mol Cell (2004) 1.95
Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol (2008) 1.93
HIF-1alpha controls extracellular matrix synthesis by epiphyseal chondrocytes. J Cell Sci (2003) 1.93
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res (2009) 1.90
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A (2006) 1.89
Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr (2009) 1.89
Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat (2011) 1.87
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol (2009) 1.83
Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81
PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A (2008) 1.80
The mouse cornea micropocket angiogenesis assay. Nat Protoc (2007) 1.74
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72
Targeted deletion of the calcineurin inhibitor DSCR1 suppresses tumor growth. Cancer Cell (2008) 1.72
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics (2006) 1.60
Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg (2005) 1.59
Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant (2007) 1.57
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat (2010) 1.57
Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem (2002) 1.56
Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J (2006) 1.52
Forty-year journey of angiogenesis translational research. Sci Transl Med (2011) 1.51
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Mol Cancer Ther (2008) 1.47
Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J (2008) 1.46
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42
Hypothesis: Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients is a major underlying reason why adjuvant chemotherapy works particularly well for those patients. Breast Cancer Res (2004) 1.42
Application of two-dimensional gel-based mass spectrometry to functionally dissect resistance to targeted cancer therapy. Proteomics Clin Appl (2013) 1.39
Tumor dormancy due to failure of angiogenesis: role of the microenvironment. Clin Exp Metastasis (2008) 1.38
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg (2003) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 1.33
Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res (2005) 1.33
Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res (2005) 1.33
Activation of hypoxia inducible factor 1 is a general phenomenon in infections with human pathogens. PLoS One (2010) 1.29
Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci U S A (2005) 1.28
S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res (2002) 1.28
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One (2010) 1.27
Platelet-associated PF-4 as a biomarker of early tumor growth. Blood (2007) 1.26
PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One (2007) 1.24
HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells (2014) 1.23
Lymphangiogenesis new mechanisms. Ann N Y Acad Sci (2002) 1.23
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Radiation abscopal antitumor effect is mediated through p53. Cancer Res (2003) 1.22
Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J (2006) 1.21
An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol (2008) 1.19
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res (2004) 1.19
Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res (2008) 1.19
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol (2008) 1.18
Tumor-vascular interactions and tumor dormancy. APMIS (2008) 1.16
Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol (2003) 1.16
Hypoxia and HIF-1alpha in osteoarthritis. Int Orthop (2004) 1.13
The effect of genetic diversity on angiogenesis. Exp Cell Res (2006) 1.13
Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci U S A (2012) 1.12
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis (2012) 1.12
Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics (2002) 1.12
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res (2007) 1.11
A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res (2005) 1.10
Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J (2003) 1.10
Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril (2005) 1.08
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia (2003) 1.08
The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors. Exp Cell Res (2008) 1.08
Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. Am J Pathol (2006) 1.07
Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. Cell Microbiol (2003) 1.07
The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J (2009) 1.07
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res (2003) 1.06
HIF-prolyl hydroxylases in the rat kidney: physiologic expression patterns and regulation in acute kidney injury. Am J Pathol (2009) 1.06
Angiogenesis in wounds treated by microdeformational wound therapy. Ann Surg (2011) 1.05
Adipose tissue growth and regression are regulated by angiopoietin-1. Biochem Biophys Res Commun (2003) 1.05
Adenovirus-mediated delivery of a soluble form of the VEGF receptor Flk1 delays the growth of murine and human pancreatic adenocarcinoma in mice. Surgery (2002) 1.04